Evotec Takes The Lead On EU-Backed Antibiotic R&D Project
Executive Summary
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
You may also be interested in...
Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia
Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.